📊 CAMP Key Takeaways
Investment Thesis
Camp4 Therapeutics is a pre-revenue pharmaceutical company with severely negative profitability metrics and ongoing cash burn, losing $80.4M on just $3.5M revenue despite 436.5% YoY growth. While the company maintains adequate liquidity with $109.5M cash and a 7.35x current ratio, the massive operating losses (-1502% margin), deteriorating net margins (-2299%), and negative free cash flow of -$29.8M indicate unsustainable business operations. At current burn rates, the company faces critical pressure and requires either significant inflection in revenue or successful clinical outcomes to achieve viability.
CAMP Strengths
- Strong liquid position with $109.5M cash providing runway for operations
- Impressive revenue growth of 436.5% YoY demonstrates commercial progress
- Minimal debt burden with 0.00x debt-to-equity ratio reducing financial stress
- Early stage pharmaceutical company typical burn pattern expected during development
CAMP Risks
- Operating cash burn of -$29.8M annually with negative FCF requires significant runway management
- Net margin of -2299% and operating margin of -1502% indicate severe unprofitability
- Revenue base of $3.5M is insufficient to support operating expenses of $52.6M+ suggesting either unproven commercialization or early product launch phase
- Negative ROE of -168.5% and ROA of -68.2% indicate substantial shareholder value destruction
- Pharmaceutical development risk: success dependent on clinical trial outcomes and regulatory approval
Key Metrics to Watch
- Quarterly revenue growth trajectory and ability to scale commercial operations
- Monthly operating cash burn rate and cash runway projections
- Clinical trial progress and regulatory milestones for pipeline candidates
- Gross margin expansion as revenue scales to profitability inflection point
- Operating expense ratio improvement through operational leverage
CAMP Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 7.35x current ratio provides a solid financial cushion.
CAMP Profitability Ratios
CAMP vs Healthcare Sector
How Camp4 Therapeutics Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CAMP Balance Sheet & Liquidity
CAMP 5-Year Financial Trend
5-Year Trend Summary: Camp4 Therapeutics Corp's revenue has grown significantly by 437% over the 5-year period, indicating strong business expansion. The most recent EPS of $-11.04 indicates the company is currently unprofitable.
CAMP Growth Metrics (YoY)
CAMP Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$12.4M | $-0.55 |
| Q2 2025 | N/A | -$12.4M | $-0.62 |
| Q1 2025 | N/A | -$12.4M | $-0.62 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CAMP Capital Allocation
CAMP SEC Filings
Access official SEC EDGAR filings for Camp4 Therapeutics Corp (CIK: 0001736730)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CAMP
What is the AI rating for CAMP?
Camp4 Therapeutics Corp (CAMP) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CAMP's key strengths?
Strong liquid position with $109.5M cash providing runway for operations. Impressive revenue growth of 436.5% YoY demonstrates commercial progress.
What are the risks of investing in CAMP?
Operating cash burn of -$29.8M annually with negative FCF requires significant runway management. Net margin of -2299% and operating margin of -1502% indicate severe unprofitability.
What is CAMP's revenue and growth?
Camp4 Therapeutics Corp reported revenue of $3.5M.
Does CAMP pay dividends?
Camp4 Therapeutics Corp does not currently pay dividends.
Where can I find CAMP SEC filings?
Official SEC filings for Camp4 Therapeutics Corp (CIK: 0001736730) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CAMP's EPS?
Camp4 Therapeutics Corp has a diluted EPS of $-2.65.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.